- Johnson & Johnson and Legend Biotech have expanded their manufacturing deal with Novartis to increase the production of Carvykti.
- The agreement covers Carvykti supply for clinical trials outside of China.
Johnson & Johnson and Legend Biotech have announced the expansion of their partnership with Novartis to manufacture their multiple myeloma treatment, CAR-T Caryvkti until the end of 2029.
The deal will see Novartis supply Carvykti from its cell therapy site in Morris Plains, New Jersey. This site is located just 20 miles from Johnson & Johnson and Legend’s CAR-T facility in Raritan, New Jersey.